Drug Submissions for Generic Drug Products
On this page …
- Generic Drug Listings in B.C.
- Maximum Accepted List Price (MALP)
- When a Drug Does Not Meet the MALP
- Benefit Status of Generic Drugs
- Pan-Canadian Pharmaceutical Alliance Generic Initiatives Tiered Pricing Framework
- Generic Drug Submission Procedures
In November 2016, the Drug Price Regulation was amended to improve the generic drug listing process in B.C.
Effective April 1, 2017, PharmaCare no longer has an annual confirmation of generic drug pricing. Manufacturers are not required to participate in an annual price confirmation process to ensure continued listing of their products.
PharmaCare continues to review submissions for new generic drugs and to update the generic formulary each month.
Any drugs on the PharmaCare formulary as of April 1, 2017, will remain on the formulary at their current reimbursement level until price changes are processed or until coverage of the drug is removed.
Maximum Accepted List Price
The Regulation establishes a Maximum Accepted List Price (MALP) for every generic drug in the Low Cost Alternative (LCA) Program. Only generic drugs priced at or below the MALP are considered for PharmaCare coverage, unless an exception is made for a specific generic drug on a provisional basis.
On January 29, 2018, the pan-Canadian Pharmaceutical Alliance (pCPA) and the Canadian Generic Pharmaceutical Association (CGPA) announced a new 5-year initiative that will reduce prices of most common generic drugs. For more information, please see PharmaCare Newsletter 18-004.
The maximum price that manufacturers can charge for generic LCA products is:
Effective April 1, 2018, most of the following generic drugs that are subject to Pan-Canadian Pharmaceutical Alliance (pCPA) Generic Initiative pricing will be reimbursed at approximately 18% of the equivalent brand name product, plus an 8% markup. Items marked with an asterisk (*) are non-benefits and will not be reimbursed by PharmaCare.
|amiodarone||candesartan HCTZ°||eletriptan*||lamotrigine||pravastatin||telmisartan HCTZ|
ºExclusivity listing of candesartan and candesartan HCTZ will be maintained
- Effective April 1, 2018, most of the following generic drugs that are subject to Pan-Canadian Pharmaceutical Alliance (pCPA) Generic Initiative pricing will be reimbursed at approximately 10% of the equivalent brand name product, plus an 8% markup. Items marked with an asterisk (*) are non-benefits and will not be reimbursed by PharmaCare.
|atorvastatin||ezetimibe*||olanzapine ODT||rabeprazole EC||simvastatin|
- 20% of the equivalent brand product list price for all other oral solids
- 35% of the equivalent brand product list price for all other drugs
For more complete pricing details, please refer to the list of molecules subject to pan-Canadian generic pricing, with their established price points.
When granting an exception to the MALP for a generic drug, PharmaCare grants the exception on a provisional basis only. PharmaCare reserves the right to rescind the exception, remove the full benefit status, and delist the drug.
For information about LCA categories, applicable MALPs, and current listing and reimbursement information for products subject to the LCA Program, consult the LCA/RDP Data Files.
Manufacturers with questions about the applicable MALP for their product may contact PharmaCare at firstname.lastname@example.org.
When a Drug Does Not Meet the MALP
Unless an exception is made for a specific generic drug, a manufacturer must confirm that its generic drug product will be priced at or below the MALP.
If PharmaCare does not receive confirmation of this from a manufacturer, the drug is not be eligible for PharmaCare coverage. This applies even to generic drugs that have been eligible for PharmaCare reimbursement previosuly, as they may be removed from the PharmaCare formulary.
Benefit Status of Generic Drugs
Generic drugs in an LCA category are listed as full benefits. PharmaCare does not cover generic drugs as partial benefits.
Full benefit products are generally reimbursed to a maximum of the supplier list price, plus a mark-up of 8%. Drugs subject to the High Cost Drugs policy are reimbursed to a maximum of the manufacturer list price, plus a mark-up of 5% or less.
If a drug is subject to both the LCA Program and the Reference Drug Program, the lowest maximum reimbursement amount applies.
Pan-Canadian Pharmaceutical Alliance (pCPA) Generic Initiatives
Tiered Pricing Framework
The Canadian Generic Pharmaceutical Association, British Columbia, and other participating provinces and territories reached an agreement on a Tiered Pricing Framework for generic drugs. BC PharmaCare implements this framework in its generic drug pricing process where possible. Tiered pricing does not supersede existing PharmaCare regulation and policies, such as the LCA Program MALP.
Tiered pricing is applied to certain LCA categories based on the number of competitors in that LCA category.
# of Competitors in the Market
75% of the brand reference price
50% of the brand reference price
Three or more
25% of the brand reference price (Oral Solids)
35% of the brand reference price (Non-oral Solids)
Manufacturers are expected to submit prices in accordance with the Tiered Pricing Framework. If there is any change in the number of competitors that causes a lower tier base price, the supplier must reduce their list price to the appropriate tier base price if they want their drugs to be considered for coverage in that category.
Generic Drug Submission Procedures
All prescription drugs submitted for inclusion as benefits under the PharmaCare program must undergo a review.
Effective April 1, 2017, PharmaCare accepts submissions at any time throughout the year. Submissions are accepted only if the manufacturer can confirm supply availability and enters submissions in the appropriate workbook, in the required format.
Before making submissions (other than exclusive listing submissions) to PharmaCare, manufacturers seeking coverage for new generic drugs must submit a Tiered Pricing Confirmation Form to the pan-Canadian Pharmaceutical Alliance Centralized Price Confirmation Process. For further details, refer to the Centralized Price Confirmation Process section of the Pan-Canadian Generics page.
Required Documents for Submission
Regular submissions must include the following documents:
- Scanned copy of the signed British Columbia Generic Drug Listing Terms and Conditions (PDF)
- Generic Listing Submission Workbook (XLS)
- Scanned copy of the Notice of Compliance (NOC) document issued by Health Canada showing the applicable Drug Identification Numbers (DINs)
These documents must be attached in a single email to email@example.com. The email subject line must read "Generic Listing Submission for [chemical name of drug] from [manufacturer name]."
Guidance on the Amendment to Section 3.1 of the Drug Price Regulation (November 2016)—Exclusive Listing Submissions
PharmaCare prioritizes submissions received at or below the MALP. If a manufacturer makes an exclusive listing submission for an LCA category that contains only provisionally listed generic drugs, PharmaCare reviews their submission under a separate process. If accepted, that drug will be the sole generic drug listed in that LCA category for a period of up to 12 months.
For more information, see Guidance on the Amendment to Section 3.1 of the Drug Price Regulation.
Submitting Multiple Strengths and Formulations
Regular submissions for different strengths of the same chemical in the same formulation must be included in a single submission email, using one common Generic Listing Submission Workbook. The submission must include:
- One signed British Columbia Generic Drug Listing Terms and Conditions (PDF)
- The applicable NOCs of all strengths submitted
Submitting Price Changes
To request a price change (increase or decrease), follow the associated procedures.
Notification of Listing Decisions
PharmaCare notifies manufacturers of listing decisions by email. Listing decisions are also published online in the LCA/RDP Data Files.
Price increases for 2018 will be announced May 1, 2018, in the LCA/RDP Data Files.
Notification of Price Changes Resulting from Tiered Pricing Framework
To help pharmacies manage their inventory and to lessen the impact of price reductions, pharmacies are given 14 days’ advance notice of changes in pricing resulting from the tiered pricing model through an update to the LCA/RDP Data Files. During the 14-day notification period, suppliers are not obligated to reduce their drug price.
- PharmaCare Policy Manual, LCA/RDP policies, Sections 5.11 and 5.12 (PDF)
- Current listing and reimbursement data files for LCA/RDP, including
- LCA/RDP data file interpretation documents, including
- British Columbia Generic Drug Listing Terms and Conditions (PDF)
- Generic Listing Submission Workbook (XLS)
- Exclusive Listing Submission Workbook (Exhibit A) (XLS)
- Exclusive Listing Agreement (PDF)
- Drug Submission Procedures for Patented Drug Products and Biosimilars
- Submitting Price Changes for Generic Drugs
- Submitting Price Changes for Brand Name and Single-Source Generic Drugs
- Pan-Canadian Tiered Pricing Framework